Fresenius Medical Care stock falls after 2.9 percent Xetra drop

Published on 09/18/2026 at 12:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius Medical Care stock closed at EUR 38.94 on Xetra on September 17, 2026, down 2.9 percent from the previous session. The shares remain below the mid-point of their 52-week range as investors weigh recent underperformance in the DAX.

Moderner Dialyseraum mit Hämodialysegeräten und Patientenliegen bei Tageslicht — Ein fotorealistisches Bild eines modernen Dialyseraums mit mehreren Hämodialysegeräten und Patientenliegen in Reihe, ruhigem Tageslicht durch große Fenster – typisch für die Behandlungszentren von Fresenius Medical Care AG (ISIN DE0005785802), Illustration mit AI erstellt.

Fresenius Medical Care AG & Co. KGaA (ISIN DE0005785802) stock traded around EUR 38.94 on Xetra at the close on September 17, 2026, marking a decline of about 2.9 percent compared with a prior-session level near EUR 40.03 and signaling fresh pressure on the dialysis specialist’s shares in the DAX environment.

Recent Xetra drop and DAX context

According to Ad-hoc-news, Fresenius Medical Care stock closed around EUR 38.94 on Xetra on September 17, 2026, down roughly 2.9 percent from about EUR 40.03 at the previous close, highlighting a notable single-session setback for investors.

In the DAX overview for the same trading day, Fresenius Medical Care was listed among the weakest index constituents, with the shares down 2.46 percent versus the prior day, placing the company alongside other underperformers such as Heidelberg Materials and Deutsche Telekom, as reported by XTB on September 18, 2026.

ADR performance and valuation signal

On the US market, the American Depositary Receipt (ADR) of Fresenius Medical Care trades under the ticker FMS on the New York Stock Exchange, giving international investors an additional way to access the stock.

As of September 17, 2026, a performance snapshot cited by GuruFocus indicated that Fresenius Medical Care ADRs traded at USD 22.07, down 3.9 percent on that day, and around 8.0 percent below the platform’s GF Value estimate of USD 24.00, implying a moderate valuation discount.

Based on factor scoring presented by GuruFocus, Fresenius Medical Care earned a GF Score of 74 out of 100, reflecting above-average overall performance, with profitability rated 7 out of 10 and valuation 9 out of 10, but growth only 3 out of 10, pointing to a mix of strengths and weaknesses that investors need to balance.

Analyst stance and risk backdrop

The recent share-price setback on Xetra and the underperformance in the DAX suggest that the market is currently focusing on execution risks and the broader healthcare environment, even as selected valuation indicators point to an above-average profile.

For investors, the key risk highlighted in the latest DAX commentary is that Fresenius Medical Care shares were counted among the top index laggards on September 17, 2026, underscoring the possibility that any further operational disappointment or cost pressure could lead to continued volatility, as implied by the negative performance noted by XTB.

Stock level after the latest session

Fresenius Medical Care stock therefore enters September 18, 2026, trading below the prior-session level, with the Xetra closing price of EUR 38.94 on September 17, 2026 acting as the latest reference point in euros, while the ADR price of USD 22.07 on the same date shows that the US listing mirrors the recent weakness and still stands around 8.0 percent below the cited GF Value estimate.